Einrichtungen, die zum Universitätsklinikum Erlangen gehören

Cobitolimod for Moderate-to-Severe Left-Sided Ulcerative Colitis (CONDUCT): A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial (2020) Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, et al. Conference contribution Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study (2020) D'Agostino M, Schett G, Lopez-Rdz A, Senolt L, Maldonado-Cocco J, Burgos-Vargas R, Naredo E, et al. Conference contribution Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up (2020) Kwoh CK, Guermazi A, Ashbeck E, Hu C, Bedrick E, Sharma L, Eaton C, et al. Conference contribution Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24 (2020) Smolen J, Behrens F, Liu-Leage S, Sapin C, De La Torre I, Meszaros G, Schett G, et al. Conference contribution The Joint Association of Steps/day and Typical Sedentary Bout Length with Worsening Knee Cartilage Damage over Two Years: The MOST Study (2020) Voinier D, Neogi T, Stefanik J, Guermazi A, Roemer F, Master H, Thoma L, et al. Conference contribution Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial (2020) Baraliakos X, Gossec L, Pournara E, Jeka S, Blanco R, D'Angelo S, Schett G, et al. Conference contribution Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) (2020) Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, et al. Conference contribution Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis (2020) Mease P, Van Der Heijde D, Kirkham B, Schett G, Orbai AM, Ritchlin C, Merola J, et al. Conference contribution Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib (2020) Matteson E, Distler O, Distler J, Kuwana M, Pope J, Seibold J, James A, et al. Conference contribution Microbiota-induced Intestinal Barrier Dysfunction Initiates the Shuttling of Immune Cells from the Gut to the Joints (2020) Tajik N, Frech M, Brandl C, Canete J, Ciccia F, Schett G, Zaiss M Conference contribution